🇺🇸 FDA
Patent

US 9585935

Intranasal oxytocin treatment to improve schizophrenia

granted A61KA61K38/095A61K9/0043

Quick answer

US patent 9585935 (Intranasal oxytocin treatment to improve schizophrenia) held by The Regents of the University of California expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K38/095, A61K9/0043, A61P, A61P25/00